TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,15%(-0,00100) 1D
15 հոկ, 08:03:18 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
0,67 €
High
0,67 €
Low
0,67 €
Mkt. cap
191,64 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,48 €
52-wk low
0,60 €
EPS
-0,17 €
No. of employees
152
Open
0,67 €
High
0,67 €
Low
0,67 €
Mkt. cap
191,64 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,48 €
52-wk low
0,60 €
EPS
-0,17 €
No. of employees
152
News stories
From web sources and news partners
FinancialContent
·
58 րոպե առաջ
Marsh (NYSE:MRSH) Surprises With Q3 2026 Sales
Yahoo Finance
·
27 րոպե առաջ
The S&P 500 Is Expecting Something Extraordinary. History Says Investors Should Be Careful What They Wish For.
Seeking Alpha
·
10 րոպե առաջ
The Outlook For S&P 500 Dividends In October 2026 (undefined:SPX)
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA